Filter Results:
(128)
Show Results For
- All HBS Web
(373)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(373)
- People (2)
- News (140)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Sort by
- 26 Nov 2001
- Research & Ideas
Women Entrepreneurs Use Springboard for Funding
personalize healthcare and benefits, and Carol Nacy of Sequella, Inc., a biotech firm focused on controlling global infectious diseases, especially tuberculosis. Most of the companies were already up and running. Their funding to date has... View Details
Keywords: by Martha Lagace
- 12 May 2009
- First Look
First Look: May 12, 2009
this situation, donations are likely to decline, investment surplus has declined and biotech partners are challenged to finance joint projects as well as their own operations. Beall is striving to find a cure for cystic fibrosis while... View Details
Keywords: Martha Lagace
- 19 Sep 2012
- Research & Ideas
Book Excerpt: “The Architecture of Innovation”
but the fund achieved impressive successes. For instance, it invested in biotech firms like Amgen, Cephalon, and Sepracor, and coinvested with major venture firms such as Kleiner Perkins and New Enterprise Associates. Its compensation... View Details
- 24 May 2011
- First Look
First Look: May 24
case:http://cb.hbsp.harvard.edu/cb/product/211086-PDF-ENG Innovation and Growth at Actelion Ltd Gary P. Pisano, Daniela Beyersdorfer, and Ruth DittrichHarvard Business School Case 611-065 : In late 2010, Jean-Paul Clozel, CEO of the Swiss View Details
Keywords: Sean Silverthorne
- 04 Jun 2007
- Research & Ideas
Is Health Care Making You Better—or Dead?
technological innovation, which is how the biotechs and some of the medical devices can get through these hurdles. But for a health service innovation, the payment hurdles are so massive it's masochistic. Then if you go into competition... View Details
- 20 Jul 2015
- Research & Ideas
Globalization Hasn’t Killed the Manufacturing Cluster
the federal government to create new clusters in the United States. He points to the rise of biotech in Harvard's backyard, which began despite government opposition in the 1970s. Clusters "tend to emerge much more organically, and they... View Details
- 06 Feb 2007
- First Look
First Look: February 6, 2007
Harvard Business School Supplement 107-049 Supplements the (A) case. Purchase this supplement: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=107049 Monsanto: Realizing Biotech Value in Brazil Harvard Business School Case... View Details
Keywords: Martha Lagace
- 17 Oct 2006
- First Look
First Look: October 17, 2006
founded by a young venture capitalist and a university professor to exploit recombinant DNA technology. Thirty years and more than $300 billion in investments later, only a handful of biotech firms have matched Genentech's success or even... View Details
Keywords: Sean Silverthorne
- 12 Oct 2006
- First Look
First Look: October 12, 2006
http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=707438 PublicationsScience Business: Promise, Performance and the Future of Biotech Author:Gary P. Pisano Publication:Harvard Business School Press (forthcoming) Abstract... View Details
Keywords: Sean Silverthorne
- 29 Oct 2000
- Research & Ideas
The Entrepreneurial Venture: A Conversation
decisions? O'Lear: I have been involved in microeconomic (company specific) upheaval. Prior to starting a company with two others, I worked at two high-tech companies: a privately held cardiac ultrasound imaging company and a VC-backed View Details
Keywords: by Susan Young
- 01 Mar 2018
- What Do You Think?
Two Decades Later, is the 'New Economy' Finally Here?
second of these books, Exponential Organizations (“ExOs”), explores the impact of new technologies on organizations. These are organizations driven by such things as AI, robotics, biotech and bioinformatics, data science, and 3D printing.... View Details
Keywords: by James Heskett
- 19 Mar 2006
- Research & Ideas
Unlocking Your Investment Capital
Neither an asset's cost nor its size specifies its riskiness. For example, consider two assets, $1 billion of a single-drug biotech stock and $1 billion of U.S. Treasury bonds: Each has the same cost and size but they have radically... View Details
- 23 Oct 2018
- First Look
New Research and Ideas, October 23, 2018
case:https://hbsp.harvard.edu/product/318082-PDF-ENG Harvard Business School Case 318-083 Sandra Brown Goes Digital (B): The Commitment Decision Sandra Brown, a middle manager at a biotech company who has led internal and external... View Details
Keywords: Dina Gerdeman
- 25 Feb 2014
- First Look
First Look: February 25
recent firm performance? Purchase this case: http://hbr.org/product/say-on-pay-qualcomm-inc-shareholders-vote-maybe-in-2012/an/114005-PDF-ENG Harvard Business School Case 213-047 Aqua Bounty Valuation of a pre-revenue biotech company at... View Details
Keywords: Sean Silverthorne
- 08 Sep 2010
- First Look
First Look: September 8, 2010
for a cure; the doubts and obstacles he experiences along the way; and the current options Kremer faces, from returning home to spend time with family to founding a new biotech venture. Through this stark, realistic, and inspiring... View Details
Keywords: Sean Silverthorne
- 12 Sep 2006
- First Look
First Look: September 12, 2006
organization's relational capacity. The benefits will reverberate throughout every dimension of the company's work. Financial Contracting in Biotech Strategic Alliances Authors:David T. Robinson and Toby E. Stuart Periodical:Journal of... View Details
Keywords: Sean Silverthorne
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
prescription drugs that in 1992 it spun off its remaining chemical business to its stockholders. In addition, the American Cyanamid purchase included Immunex, one of the very few biotech startups that had surpassed $100 million in... View Details
- 17 Mar 2009
- First Look
First Look: March 17, 2009
Download the paper: http://www.hbs.edu/research/pdf/09-099.pdf Cases & Course MaterialsAvid Radiopharmaceuticals: The Venture Debt Question Harvard Business School Case 809-086 The CEO of a promising biotech company must decide how... View Details
Keywords: Martha Lagace
- 01 May 2007
- First Look
First Look: May 1, 2007
drug development process; threats from biotech and generics competitors; pharmaceutical manufacturing, selling, and marketing; and pharmaceutical consumption in Europe, the third world, and the U.S. Merck and Pfizer are analyzed in-depth... View Details
Keywords: Sean Silverthorne
- 20 Nov 2006
- Research & Ideas
Open Source Science: A New Model for Innovation
four-and-a-half year period. Problems involved everything from biotech to consumer products and agrochemicals. Thanks to broadcasting, nearly one-third of the previously unsolved problems found successful solutions. "Innovations... View Details
Keywords: by Martha Lagace